ImmuCell Corporation
ICCC
$9.92
$0.151.54%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 38.50% | -14.57% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 38.50% | -14.57% | |||
| Cost of Revenue | 50.04% | -13.34% | |||
| Gross Profit | 23.15% | -16.14% | |||
| SG&A Expenses | -14.52% | 16.39% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 25.48% | -6.63% | |||
| Operating Income | 3,591.54% | -96.47% | |||
| Income Before Tax | -2,003.33% | -126.86% | |||
| Income Tax Expenses | -26.67% | 136.84% | |||
| Earnings from Continuing Operations | -1,939.44% | -127.83% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -1,939.44% | -127.83% | |||
| EBIT | 3,591.54% | -96.47% | |||
| EBITDA | 107.15% | -43.51% | |||
| EPS Basic | -1,945.45% | -127.70% | |||
| Normalized Basic EPS | 1,022.00% | -114.53% | |||
| EPS Diluted | -1,475.00% | -135.97% | |||
| Normalized Diluted EPS | 1,008.00% | -114.53% | |||
| Average Basic Shares Outstanding | 0.00% | 0.16% | |||
| Average Diluted Shares Outstanding | 1.60% | 0.16% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||